OUTLOOK THERAPEUTICS INC (OTLK NASDAQ) stock market data APIs
$0.2164
0.01(4.6%)
as of May 7, 2026
Try our APIs with
free plan!
OUTLOOK THERAPEUTICS INC Financial Data Overview
Price chart is built with
Anychart
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Prev. Close
0.2164
Open
0.2277
High
0.2279
Low
0.2045
52 wk Range
0.1611-3.39
Market Cap
26 044 K
Shares Outstanding
121 M
Revenue
206 K
EPS
-0.22
Beta
0.333
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with OUTLOOK THERAPEUTICS INC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OUTLOOK THERAPEUTICS INC data using free add-ons & libraries
Get OUTLOOK THERAPEUTICS INC Fundamental Data
OUTLOOK THERAPEUTICS INC Fundamental data includes:
- Net Revenue: 206 K
- EBITDA: -58 820 440
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get OUTLOOK THERAPEUTICS INC Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-02-17
- EPS/Forecast: -0.1733
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OUTLOOK THERAPEUTICS INC News
New
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the sta...
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...
FDA Accepts Outlook Therapeutics' FDRR To Resolve ONS-5010/LYTENAVA Regulatory Issues; Stock Up
(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a clinical-stage biotechnology company, announced on Tuesday that the U.S. Food and Drug Administration FDA has accepted its Formal Dispute Resolution Re...
Outlook Therapeutics Hits 52-Week Low As It Launches Proposed Public Offering
(RTTNews) - Outlook Therapeutics, Inc. (OTLK) announced that it has proposed a best-efforts public offering of its common stock and accompanying warrants, a move that comes as the company's shares hov...
Get OUTLOOK THERAPEUTICS INC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
